Aims: The introduction of immunotherapy for patients with head and neck squamous cell carcinoma (HNSCC) raises the need for harmonisation between different types of antibody and immunohistochemistry platform for evaluating the expression of PD-L1 by use of the combined positive score (CPS) in this tumour. The aim of this study was to compare the expression of PD-L1 as determined with the CPS and two widely used assays (the 22C3 PharmDx assay and the SP263 assay) in a cohort of HNSCCs.
Methods And Results: We analysed 43 whole sections of HNSCC with two different anti-PD-L1 antibodies, 22C3 and SP263. The results, expressed as the CPS, were evaluated by 10 trained pathologists and statistical analyses were performed. We found a very similar results for PD-L1 expression between the 22C3 PharmDx assay and the SP263 assay in our cohort, and a strong and significant correlation between the two assays for all specimens (P < 0.0001). The interobserver reliability among pathologists for the continuous scores of CPS with the intraclass correlation coefficient and the correlation between the two assays were both good. Moreover, the rate of agreement between assays was high at all cut-offs and was best for the most relevant cut-off of CPS ≥ 1, and the kappa values were always in the range of almost perfect.
Conclusions: Two different assays (the 22C3 PharmDx assay and SP263 assay) for PD-L1 in HNSCC showed high agreement. These data suggest that these two assays are interchangeable in the selection of patients with HNSCC for immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299113 | PMC |
| http://dx.doi.org/10.1111/his.14562 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression.
Oncologist
September 2024
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Background: Claudin 18.2 (CLDN18.2) is a promising target for targeted therapies in gastric cancer (GC).
View Article and Find Full Text PDFConcordance between four PD-L1 immunohistochemical assays and 22C3 pharmDx assay in esophageal squamous cell carcinoma in a multicenter study.
J Natl Cancer Cent
June 2024
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: The prediction of response to immunotherapy mostly depends on the programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) status, and the 22C3 pharmDx assay has been approved in esophageal squamous cell carcinoma (ESCC). However, the widespread use of the 22C3 pharmDx assay is limited due to its availability. Thus, alternative PD-L1 assays are needed.
View Article and Find Full Text PDFComparison of PD-L1 assays in head and neck carcinoma.
Pathology
December 2024
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address:
Article Synopsis
- PD-L1 expression serves as a crucial biomarker in predicting how patients with head and neck squamous cell carcinoma might respond to immune checkpoint inhibitors, making it important to evaluate different testing methods.
- A study conducted at Asan Medical Center evaluated PD-L1 expression in 156 cases using various standardized assays and a laboratory-developed test, revealing good to excellent agreement among the methods.
- The results highlighted that PD-L1 expression significantly varies with tumor location and suggests that the different assays could potentially be used interchangeably for assessing PD-L1 in head and neck cancers.
Molecular Diagnostic Yield and Safety Profile of Ultrasound-Guided Lung Biopsies: A Cross-Sectional Study.
Cancers (Basel)
August 2024
U.O.C. Clinica Pneumologica L. Vanvitelli, Monaldi Hospital, A.O. dei Colli, 80131 Naples, Italy.
Background: The recent advances in precision oncology for lung cancer treatment has focused attention on the importance of obtaining appropriate specimens for tissue diagnosis as well as comprehensive molecular profiling. CT scan-guided biopsies and bronchoscopy are currently the main procedures employed for tissue sampling. However, growing evidence suggests that ultrasound-guided biopsies may represent an effective as well as safe approach in this diagnostic area.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!